How to Reconstitute SLU-PP-332

SLU-PP-332 is a small-molecule synthetic agonist of the estrogen-related receptors (ERRα, ERRβ and ERRγ), also referred to in the literature as an ERRα/β/γ agonist and classified as an exercise mimetic chemical probe [1][4]. The evidence block does not provide a sequence, molecular formula or molecular weight for this compound, so no such values are stated here. The work described below centres on the ERR nuclear receptor family and its downstream regulation of mitochondrial metabolism and exercise-responsive transcription [2].

Reconstitution is a laboratory handling step: the solid is dissolved in a suitable solvent to give a stock solution of known concentration, which is then diluted into the assay system. The evidence block does not specify a solvent, a stock concentration or a storage condition for SLU-PP-332, so none is given here. What the evidence does provide is analytical and metabolic characterisation of the compound in vitro, and a body of animal and cell-model work on ERR activation. Every finding below is attributed to the model in which it was observed.

Research Studies

SLU-PP-332 and in vitro metabolic transformation in human liver S9 fractions

SLU-PP-332 and the related pan-ERR agonist SLU-PP-915 were characterised by liquid chromatography–high resolution (tandem) mass spectrometry, and their in vitro metabolic transformation products were prepared using human liver S9 fractions [1]. The same work framed both compounds as ERR agonists under investigation as exercise mimetics, on the basis that they trigger human physiological processes similar to those initiated by physical activity, and noted that this capability prompted their consideration as compounds relevant to sports drug testing programmes [1]. For a laboratory working with the compound, the practical point is that an analytical method exists for the parent compound and for its S9-derived transformation products, which is the basis for identifying the material in a sample matrix.

SLU-PP-332 and structure–activity relationships at the ERR scaffold

SLU-PP-332 is described as a well-established exercise mimetic and a widely used chemical probe for ERR activation, but the structural features governing its potency, efficacy, selectivity and drug-like properties had not been systematically elucidated [2]. A comprehensive structure–activity relationship analysis of the SLU-PP-332 scaffold was subsequently reported, integrating chemical synthesis, cell-based functional assays, downstream gene-expression profiling and further characterisation [2]. This is cell-based and chemical work; it does not establish an in vivo exposure–response relationship.

SLU-PP-332 and ERR activation in myoblasts from inactive women

A pilot study evaluated ERR targeting in myoblasts isolated from the skeletal muscle of inactive women [3]. Twenty women undergoing hip arthroplasty for coxarthrosis were enrolled and divided into an active group (n = 10) and an inactive group (n = 10) based on self-reported physical activity, and the metabolic and expression changes associated with ERR activation were assessed in the isolated myoblasts [3]. This is an ex vivo human cell model derived from a defined surgical population; the findings belong to that population and that preparation.

SLU-PP-332 and exercise-mimetic status under anti-doping rules

Exercise mimetics mimic physical activity and have been studied for their capacity to prevent the development and progression of chronic metabolic diseases, including obesity and Type 2 diabetes [4]. The World Anti-Doping Agency prohibits the use of exercise mimetics and metabolic modulators in sports, and SLU-PP-332 has been described as a small synthetic ERRα/β/γ agonist in that context [4]. This is a regulatory and analytical framing rather than a pharmacological finding.

SLU-PP-332 and the pharmacological activation of ERRα/β/γ as an exercise mimetic

Physical inactivity contributes to the development of chronic diseases, and activation of the orphan nuclear receptors ERRα/β/γ has emerged as a molecular strategy to mimic exercise-induced benefits [5]. A systematic review addressed the physiological, molecular and clinical evidence on this approach [5]. The review is a synthesis of the field; individual findings within it retain the model and population in which they were originally observed.

SLU-PP-915 and aerobic exercise capacity in an animal model

ERRα, ERRβ and ERRγ are orphan nuclear receptors that regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle, and are described as essential for skeletal muscle adaptation to aerobic exercise [6]. An orally active ERR agonist, SLU-PP-915, was reported to enhance aerobic exercise capacity [6]. This finding concerns SLU-PP-915, not SLU-PP-332, and was observed in the model used in that study.

SLU-PP-332 and metabolic syndrome in an animal model

Physical exercise induces physiological adaptations and is effective at reducing the risk of premature death from all causes, and pharmacological exercise mimetics have been proposed as a route to treating a range of diseases including obesity and metabolic syndrome [7]. SLU-PP-332 was described in that line of work as a synthetic ERR agonist, and a synthetic ERR agonist was reported to alleviate metabolic syndrome [7]. This is animal-model work; it does not define a human dose or a human outcome.

SLU-PP-332 and comparison with SLU-PP-915 across the available evidence

The two pan-ERR agonists appear together in the analytical literature, and separately in the pharmacological literature. The table below sets out what each source covers, so that the two compounds are not conflated.

SLU-PP-332 and what the evidence does not establish

• No sequence, molecular formula or molecular weight is given for SLU-PP-332 in the evidence block.
• No solvent, stock concentration, filtration step or storage condition for reconstitution is specified in the evidence block.
• No human dose, human pharmacokinetic parameter or human clinical outcome is reported for SLU-PP-332 in the evidence block.
• The human-derived material in the block is ex vivo myoblasts from a defined surgical population [3] and human liver S9 fractions used for metabolic transformation [1]; neither is a clinical study of the compound in humans.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance, and nothing on this page should be read as a recommendation for human use. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential — https://europepmc.org/article/PMC/PMC12835572
• [2] Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling — https://europepmc.org/article/PMC/PMC13112601
• [3] Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study — https://europepmc.org/article/PMC/PMC12277287
• [4] Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes — https://pubmed.ncbi.nlm.nih.gov/41688415/
• [5] [Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications] — https://pubmed.ncbi.nlm.nih.gov/42024694/
• [6] An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity — https://pubmed.ncbi.nlm.nih.gov/41421047/
• [7] A Synthetic ERR Agonist Alleviates Metabolic Syndrome — https://europepmc.org/article/PMC/PMC10801787